Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

Background Immune checkpoint inhibitors (ICIs) are approved to treat multiple cancers. Retrospective analyses demonstrate acceptable safety of ICIs in most patients with autoimmune disease, although disease exacerbation may occur. Psoriasis vulgaris is a common, immune-mediated disease, and outcomes...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrew Haydon, Jessica C Hassel, Jeffrey A Sosman, Sunandana Chandra, Ryan Sullivan, Mario E Lacouture, Matteo Carlino, Meghan J Mooradian, Alexander Menzies, Douglas B Johnson, Fei Ye, Prachi Bhave, Steven T Chen, Georgina Long, Allison Betof Warner, Briana Rose Halle, Farzana Y Zaman, Anna K Dewan, Rebecca Irlmeier, Paras Mehta, Nicholas R Kurtansky, Jacob S Choi, Tracey S Otto, Florentia Dimitriou, Veronica M Rotemberg
Format: Article
Language:English
Published: BMJ Publishing Group 2021-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/10/e003066.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/9/10/e003066.full

Similar Items